Drug Development

Chimerix announces initiation of Phase I clinical trials of CMX001, an oral smallpox treatment

Published in Drug Week, July 28th, 2006

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced that it has received U.S. Food and Drug Administration clearance for its Investigational New Drug application for CMX001, the company's oral antiviral drug candidate for the treatment of smallpox infections and complications resulting from smallpox vaccine.

"Smallpox is a devastating bioterrorism threat and vaccination is not an option for more than 40 million Americans with compromised immune systems," said Dr. George Painter, Chimerix president and CEO. "Using our platform technology, we have developed CMX001, an orally available drug candidate. We expect CMX001 to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry